{"schema_version":"secwatch.filing_event.v1","accession":"0001722482-25-000013","form_type":"8-K","ticker":"AVTR","cik":"0001722482","company_name":"Avantor, Inc.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.589769+00:00","generated_at":"2026-05-27T00:57:48.222751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avantor Q4 organic growth 1%, adjusted EPS $0.27; full-year adjusted EPS $0.99","bullets":["Q4 net sales $1.69B, down 2% reported; organic growth 1% with bioprocessing up high-single digits.","Q4 GAAP EPS $0.73 (net income $500.4M); adjusted EPS $0.27; adjusted EBITDA margin 18.2%.","Full-year net sales $6.78B, down 3% reported; organic decline 2%; adjusted EBITDA $1.20B margin 17.7%.","Free cash flow Q4 $222.1M; full-year $768.3M; adjusted net leverage 3.2x as of Dec 31, 2024.","Bioscience Production segment Q4 net sales up 4% organic; Laboratory Solutions down 1% organic."],"urls":{"canonical":"https://secwatch.observer/filing/0001722482-25-000013","json":"https://secwatch.observer/filing/0001722482-25-000013.json","markdown":"https://secwatch.observer/filing/0001722482-25-000013.md","text":"https://secwatch.observer/filing/0001722482-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722482/000172248225000013/0001722482-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722482/000172248225000013/avtr-20250207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:57:48.222751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}